Why Compass Pathways Stock Rocketed 40% Today
Summarize this article with:
By Howard Smith – Apr 20, 2026 at 12:02PM ESTKey PointsCompass Pathways has already reported two positive phase 3 trials for treatment-resistant depression (TRD). The company's COMP360 synthetic psilocybin treatment could now be on a faster track for approval. A White House Executive Order over the weekend has some healthcare company stocks soaring today. One big winner is Compass Pathways (CMPS +42.04%). Shares of the biotechnology company rocketed more than 50% this morning and were still higher by 41.2% at noon ET. Compass is a leader in the development of a new approach to mental health treatment, concentrating on achieving results through the creation of a synthetic psilocybin therapy. Psilocybin is a naturally occurring psychedelic compound found in certain types of mushrooms, commonly referred to as "magic mushrooms." Image source: Getty Images. Phase 3 trial success President Trump's Executive Order (EO) seeks to "accelerate innovative research models and appropriate drug approvals to increase access to psychedelic drugs that could save lives and reverse the crisis of serious mental illness in America." Compass CEO Kabir Nath put out a statement lauding the attempt to accelerate the research and availability of psychedelic therapies. Nath commented, "Today's announcement aligns regulatory urgency with patient need, and we applaud the Administration for taking this important step forward in accelerating access, without compromising rigorous science." He noted that the company's COMP360 synthetic psilocybin has performed well in phase 3 trials, and that Compass is already working with the FDA toward submission for approval. ExpandNASDAQ: CMPSCompass Pathways PlcToday's Change(42.04%) $2.80Current Price$9.46Key Data PointsMarket Cap$909MDay's Range$8.63 - $10.2152wk Range$2.25 - $10.21Volume88KAvg Vol3.6M Biotech stocks can be binary investments, meaning a drug or treatment's success or failure will make the stock soar or plummet toward zero. The new EO gave investors hope that Compass Pathways' stock will be one that soars. Read NextApr 20, 2026 •By Matthew BenjaminTrump Just Fast-Tracked Psychedelic Treatments: 3 Under-the-Radar Stocks That Could Be About to SoarApr 20, 2026 •By The Motley Fool TeamStock Market Today (LIVE): Oil Spikes as U.S.
Seizes Iranian Ship; Psychedelic Drugs on the Fast TrackApr 17, 2026 •By Motley Fool StaffThe Psychedelic Revolution in Mental HealthcareApr 10, 2026 •By Keith SpeightsBest Psychedelic Stocks to Buy in 2026 and How to InvestApr 20, 2026 •By Joe TenebrusoWhy AtaiBeckley Stock Surged TodayApr 20, 2026 •By Eric VolkmanWhy Nektar Therapeutics Stock Rocked it TodayAbout the AuthorHoward Smith is a contributing Motley Fool stock market analyst covering technology and industrial stocks. Prior to The Motley Fool, Howard spent nearly 30 years supervising quality and operations in the steel industry, mostly with leading steel company Nucor. He holds a bachelor’s degree in metallurgical engineering from Lafayette College and a master’s degree in environmental engineering from Johns Hopkins University.TMFBuilt2LastStocks MentionedCompass Pathways PlcNASDAQ: CMPS$9.47(+42.12%)+$2.81*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.